Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Standard titration schedule from trials 12-week escalation protocol: Weeks 1-4: 0.6mg weekly Initiation dose Body adapts to amylin effects Minimal side effects at this level Weight loss begins (modest) Weeks 5-8: 1.2mg weekly First dose increase (doubling) Gastric slowing becomes more noticeable Appetite suppression strengthens Accelerated weight loss Weeks 9-12: 1.8mg weekly Second increase Strong satiety effects More pronounced GI effects possible Approaching maximum efficacy Week 13+: 2.4mg weekly (maintenance) Target therapeutic dose Maximum weight loss velocity Maintained indefinitely Nausea typically resolved by this point (adapted) Why this schedule works: Gradual exposure reduces side effects 4-week intervals allow full adaptation Doubling steps (0.61.22.4) are tolerable Proven in hundreds of patients Balances speed with tolerability Use our peptide calculator and peptide dosing guide at SeekPeptides for precise calculations
Just wish I could afford to buy it more often
Philipose, et al., 'Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial', N
J Translational Med
84(5): 62733 Sahajwalla CG, Helton ED, Purich ED, et al
Supplementation of specific carnitine compounds (e.g., C3DC, C10:1, and C10:2) can be potential therapeutic and/or prevention strategies for breast cancer following validation of our findings in human trials
US$ 21.94
US$ 29.37
US$ 22.54
